Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06414798 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants. | PHASE1 | COMPLETED | 60 | — | — | May 13, 2024 | Feb 8, 2025 | Feb 19, 2025 | 1 | United States |
Cmax of ABBV-1088
Tmax of ABBV-1088
Terminal phase elimination rate constant (beta) of ABBV-1088
Terminal phase elimination half-life of ABBV-1088
AUCt of ABBV-1088
AUCinf of ABBV-1088
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1- ABBV-1088 Dose A | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose A on day 1 |
| Group 1- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 2- ABBV-1088 Dose B | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose B on day 1 |
| Group 2- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 3- ABBV-1088 Dose C | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose C on day 1 |
| Group 3- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 4- ABBV-1088 Dose D | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose D on day 1 |
| Group 4- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 5- ABBV-1088 Dose E | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose E on day 1 |
| Group 5- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 6- ABBV-1088 Dose F | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose F on day 1 |
| Group 6- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Name | Type | Description |
|---|---|---|
| Drug: ABBV-1088 | DRUG | • Oral Capsule |
| Drug: Placebo for ABBV-1088 | DRUG | • Oral Capsule |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at screening. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * History of card...